Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00418366
NCT00418366
Completed
Phase 1

An Open- Label, 2 Part Study to Investigate the Pharmacokinetics, Safety, and Tolerability of MK0431(Sitagliptin Phosphate) in Patients With Varying Degrees of Renal Insufficiency

Merck Sharp & Dohme LLC0 sites24 target enrollmentJanuary 2003
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsRenal InsufficiencyHemodialysis
DrugsMK0431, sitagliptin phosphate / Duration of Treatment : 1 Days

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Renal Insufficiency
Sponsor
Merck Sharp & Dohme LLC
Enrollment
24
Primary Endpoint
Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

A study to evaluate the effect of kidney disease, from mild to severe disease, on a diabetes medication

Registry
clinicaltrials.gov
Start Date
January 2003
End Date
March 2003
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Determination of the pharmacokinetics of MK0431 (sitagliptin phosphate) in patients with renal insufficiency compared to healthy volunteers

Secondary Outcomes

  • Safety and tolerability in patients with renal insufficiency

Similar Trials

Completed
Phase 1
Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.Pharmacokinetics of IsavuconazoleHealthy VolunteersRenal Impaired
NCT01555866Astellas Pharma Global Development, Inc.49
Completed
Phase 1
Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney FunctionMild NephropathyModerate NephropathyDiabetes Mellitus
NCT00626249Mannkind Corporation36
Completed
Phase 2
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney DiseaseDiabetic Nephropathies
NCT04750577Boehringer Ingelheim243
Completed
Phase 2
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney DiseaseChronic Kidney Disease
NCT04736628Boehringer Ingelheim261
Completed
Phase 1
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney FunctionRenal Impairment
NCT06037031Pfizer16